Inotek Reports Second Quarter 2016 Financial Results And Operational Highlights
LEXINGTON, Mass.--(BUSINESS WIRE)--Inotek Pharmaceuticals Corporation (the “Company” or “Inotek”), (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today reported financial results and operational highlights for the quarter ended June 30, 2016.